Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: adenosine analogues - Purnovate

Drug Profile

Research programme: adenosine analogues - Purnovate

Latest Information Update: 24 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Purnovate
  • Developer ADial Pharmaceuticals; Purnovate; University of California, San Diego
  • Class Anti-infectives; Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Drug withdrawal therapies; Non-opioid analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis; Pain
  • Research Asthma; Cancer; Cocaine-related disorders; Diabetes mellitus; Infections; Inflammation; Inflammatory bowel diseases

Most Recent Events

  • 19 May 2022 Adial Pharmaceuticals enters into research agreement with the Medical College of Wisconsin to evaluate adenosine analogs in diabetes and non-alcoholic steatohepatitis
  • 19 May 2022 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route)
  • 04 May 2022 Purnovate enteres into a Research collaboration agreement with the University of California San Diego to evaluate Adenosine analogs for inflammatory diseases, including inflammatory bowel disease (IBD) and infectious diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top